+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Central Nervous System Drugs Market Research Reports

Intracranial Therapeutic Delivery Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Thumbnail Image

Intracranial Therapeutic Delivery Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • March 2024
  • 168 Pages
  • Global
Circadian Rhythm Sleep Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Thumbnail Image

Circadian Rhythm Sleep Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • January 2024
  • 310 Pages
  • Global
Spinal Cord Trauma Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Thumbnail Image

Spinal Cord Trauma Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • January 2024
  • 183 Pages
  • Global
Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • December 2022
  • 83 Pages
  • Global
From
Circadian Rhythm Sleep Disorders Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Circadian Rhythm Sleep Disorders Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 39 Pages
  • Global
From
Duchenne Muscular Dystrophy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Duchenne Muscular Dystrophy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • April 2022
  • 366 Pages
  • Global
From
Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • April 2022
  • 64 Pages
  • Global
From
Hepatic Encephalopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Hepatic Encephalopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • February 2022
  • 59 Pages
  • Global
From
Beta Nerve Growth Factor (Beta NGF or NGF) Drugs In Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Beta Nerve Growth Factor (Beta NGF or NGF) Drugs In Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • February 2022
  • 50 Pages
  • Global
From
Tourette Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Tourette Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • February 2022
  • 46 Pages
  • Global
From
Restless Legs Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Restless Legs Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • February 2022
  • 36 Pages
  • Global
From
P2X Purinoceptor 3 (P2RX3) - Drugs in Development, 2021 - Product Thumbnail Image

P2X Purinoceptor 3 (P2RX3) - Drugs in Development, 2021

  • Report
  • November 2021
  • 70 Pages
  • Global
From
Diabetic Peripheral Neuropathy (Metabolic Disorder) - Drugs in Development, 2021 - Product Thumbnail Image

Diabetic Peripheral Neuropathy (Metabolic Disorder) - Drugs in Development, 2021

  • Drug Pipelines
  • March 2021
  • Global
From
Migraine - Pipeline Review, H2 2020 - Product Thumbnail Image

Migraine - Pipeline Review, H2 2020

  • Drug Pipelines
  • November 2020
  • 342 Pages
  • Global
From
Spinocerebellar Ataxia (SCA) - Pipeline Review, H2 2020 - Product Thumbnail Image

Spinocerebellar Ataxia (SCA) - Pipeline Review, H2 2020

  • Drug Pipelines
  • November 2020
  • 114 Pages
  • Global
From
Glucagon Like Peptide 2 Receptor - Pipeline Review, H2 2020 - Product Thumbnail Image

Glucagon Like Peptide 2 Receptor - Pipeline Review, H2 2020

  • Drug Pipelines
  • November 2020
  • 67 Pages
  • Global
From
Transthyretin - Pipeline Review, H2 2020 - Product Thumbnail Image

Transthyretin - Pipeline Review, H2 2020

  • Drug Pipelines
  • November 2020
  • 116 Pages
  • Global
From
5-Hydroxytryptamine Receptor 6 - Pipeline Review, H2 2020 - Product Thumbnail Image

5-Hydroxytryptamine Receptor 6 - Pipeline Review, H2 2020

  • Drug Pipelines
  • October 2020
  • 62 Pages
  • Global
From
Guillain-Barre Syndrome - Pipeline Review, H2 2020 - Product Thumbnail Image

Guillain-Barre Syndrome - Pipeline Review, H2 2020

  • Drug Pipelines
  • October 2020
  • 84 Pages
  • Global
From
Traumatic Brain Injury - Pipeline Review, H2 2020 - Product Thumbnail Image

Traumatic Brain Injury - Pipeline Review, H2 2020

  • Drug Pipelines
  • July 2020
  • 440 Pages
  • Global
From
Loading Indicator

The Central Nervous System Drugs market is a sector of the pharmaceutical industry that focuses on the development and production of drugs that target the central nervous system. These drugs are used to treat a variety of conditions, including neurological disorders, mental health issues, and pain management. The market is composed of a variety of companies, ranging from large multinationals to small start-ups. The Central Nervous System Drugs market is highly competitive, with companies competing to develop the most effective and safe treatments. Companies in the market are constantly researching and developing new drugs, as well as improving existing treatments. Many of these companies are also involved in clinical trials to test the safety and efficacy of their products. Some of the major companies in the Central Nervous System Drugs market include Pfizer, GlaxoSmithKline, Merck, Novartis, and Johnson & Johnson. These companies are involved in the development and production of a wide range of CNS drugs, including antidepressants, antipsychotics, and anticonvulsants. Show Less Read more